Search Results
Your search for Matthew matches 8052 pages
Showing 7051 - 7100Risk Algorithm Using Serial CA-125 Measurements Increases the Number of Screen-Detected Ovarian Cancers
As reported in the Journal of Clinical Oncology by Menon et al, findings in the United Kingdom Collaborative Trial of Ovarian Cancer Screening indicate that the number of screen-detected ovarian cancers is doubled by using the risk of ovarian cancer algorithm (ROCA) with serial CA-125 measurements...
Addition of Necitumumab to First-Line Gemcitabine-Cisplatin Improves Overall Survival in Stage IV Squamous NSCLC
In the phase III SQUIRE trial reported in The Lancet Oncology, Thatcher et al found that the addition of the second-generation epidermal growth factor receptor (EGFR) antibody necitumumab to first-line gemcitabine-cisplatin improved overall survival among patients with stage IV squamous...
Bronchial Gene-Expression Classifier Improves Bronchoscopy Performance in Diagnosing Lung Cancer
In a study reported in The New England Journal of Medicine, Silvestri et al of the AEGIS study team found that use of a bronchial airway gene-expression classifier improved the diagnostic performance of bronchoscopy in patients being evaluated for suspected lung cancer. Study Details The study...
Addition of Bevacizumab to Radiotherapy and Temozolomide Does Not Worsen Health-Related Quality of Life in Glioblastoma Patients
In the phase III AVAglio trial, the addition of bevacizumab (Avastin) to radiotherapy and temozolomide improved progression-free survival in patients with newly diagnosed glioblastoma. As reported by Taphoorn et al in the Journal of Clinical Oncology, bevacizumab treatment did not worsen...
Higher Tumor-Infiltrating Lymphocyte Level Associated With Better Outcomes in HER2-Positive Early Breast Cancer Independent of Neoadjuvant Treatment
In an analysis of the NeoALTTO trial reported in JAMA Oncology, Salgado et al found that a higher level of tumor-infiltrating lymphocytes was associated with improved pathologic compete response rate and event-free survival independent of neoadjuvant treatment received in patients with...
Phase III Trial Confirms Benefit of Adding Bevacizumab to Chemotherapy in Chinese Patients With Advanced NSCLC
In a phase III BEYOND trial reported in the Journal of Clinical Oncology, Zhou et al found that the addition of bevacizumab to carboplatin-paclitaxel improved progression-free and overall survival in Chinese patients with locally advanced, metastatic, or recurrent advanced nonsquamous...
Addition of Number of Metastases Improves Prognostic Assessment Tool in Breast Cancer With Brain Metastases
As reported in the Journal of Clinical Oncology by Subbiah et al, the addition of number of brain metastases to the breast graded prognostic assessment (breast-GPA) tool improved the prediction of overall survival in breast cancer patients with brain metastases. The existing breast-GPA includes...
Oncolytic Immunotherapy With Talimogene Laherparepvec Improves Durable Response Rate in Advanced Melanoma
In a phase III trial reported in the Journal of Clinical Oncology, Andtbacka et al found that talimogene laherparepvec (T-VEC) treatment improved the durable response rate vs granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with unresectable stage IIIB to IV melanoma. T-VEC is...
Adjuvant Regimen Produces Good Survival Results in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
In a phase II Intergroup study (SWOG S0809) reported in the Journal of Clinical Oncology, Ben-Josef et al found that adjuvant capecitabine and gemcitabine followed by concurrent radiotherapy and capecitabine produced good survival results in patients with extrahepatic cholangiocarcinoma or...
Breast Cancer Subtype Incidence in the United States for 2011
The current annual report of cancer statistics by the American Cancer Society, Centers for Disease Control and Prevention, National Cancer Institute, and North American Association of Central Cancer Registries includes a focus on breast cancer incidence by subtype using new national-level data. The ...
Vismodegib Safety Profile in Long-Term ‘Real-World’ Use in Advanced Basal Cell Carcinoma
In a preplanned interim analysis of the international open-label STEVIE trial reported in The Lancet Oncology, Basset-Seguin et al have provided safety data and efficacy outcomes with the use of vismodegib (Erivedge) for 1 year in patients with advanced basal cell carcinoma. STEVIE was designed to...
Minority of Medicare Patients Have Adequate Cardiac Monitoring During Adjuvant Trastuzumab-Based Chemotherapy for Breast Cancer
In a study reported in the Journal of Clinical Oncology, Chavez-MacGregor et al found that the majority of older breast cancer patients receiving trastuzumab (Herceptin)-based chemotherapy do not receive adequate cardiac monitoring. Study Details The study involved 2,203 patients aged ≥...
UK Trial Shows Neoadjuvant Platinum-Based Chemotherapy Noninferior to Adjuvant Chemotherapy in Advanced Ovarian Cancer
In the UK phase III CHORUS trial reported in The Lancet, Kehoe et al found that a strategy of three cycles of platinum-based chemotherapy followed by delayed surgery and three additional cycles of chemotherapy was associated with overall survival noninferior to that achieved with surgery followed...
Second-Line Dovitinib Shows Some Activity in FGFR2-Mutant and FGFR2-Nonmutant Advanced Endometrial Cancer
In a phase II study reported in The Lancet Oncology, Konecny et al found that the multi–tyrosine kinase inhibitor dovitinib appeared to delay progression in some patients as second-line treatment in fibroblast growth factor receptor 2 (FGFR2)-mutant and -nonmutant advanced or metastatic...
Regorafenib Improves Overall Survival in Asian Patients With Previously Treated Metastatic Colorectal Cancer
In the phase III CONCUR trial reported in The Lancet Oncology, Li et al found that the multikinase inhibitor regorafenib (Stivarga) improved overall survival vs placebo in Asian patients with previously treated metastatic colorectal cancer. Regorafenib has been approved by the U.S. Food and Drug...
Hedgehog Inhibitor Sonidegib Active in Advanced Basal Cell Carcinoma
In the phase II BOLT trial reported in The Lancet Oncology, Migden et al found that the hedgehog pathway signaling inhibitor sonidegib produced responses in patients with locally advanced or metastatic basal cell carcinoma at 200-mg and 800-mg dose levels. The lower dose appeared to be associated...
Pazopanib Plus Octreotide Active in Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
In a phase II study reported in The Lancet Oncology, Phan et al found that the VEGFR-1, -2, -3 inhibitor pazopanib (Votrient) plus depot octreotide produced responses in patients with advanced well-differentiated neuroendocrine tumors. No responses were observed in patients with carcinoid tumors....
Obesity Poses Greater Prostate Cancer Risk for African American vs White Men
In an analysis of participants in the SELECT prevention trial reported in JAMA Oncology, Barrington et al found that obesity in African American men was associated with a greater risk of prostate cancer than in white men. African American men have the highest prostate cancer incidence and mortality ...
Polish Study Shows Inherited PALB2 Mutation Confers Greater Risk and Poorer Outcome of Breast Cancer
In a Polish prospective cohort analysis reported in The Lancet Oncology, Cybulski et al found that PALB2 mutation carriers had increased risk of breast cancer and that those with breast cancer had significantly reduced long-term survival. Study Details In the study, genotyping for two...
Omega-3 Fatty Acids and Placebo Reduce Aromatase Inhibitor–Related Musculoskeletal Pain in Early Breast Cancer
In the SWOG S0927 trial reported in the Journal of Clinical Oncology, Hershman et al found that both omega-3 fatty acids and placebo resulted in marked persistent reductions in aromatase inhibitor–related arthralgia among patients with early breast cancer, with no difference between...
Histologic Subtype Classification of Lung Adenocarcinoma Predicts Disease-Free but Not Overall Survival Benefit From Adjuvant Chemotherapy
In an analysis reported in the Journal of Clinical Oncology, Tsao et al found that classification by histologic subtype for invasive lung adenocarcinoma was not predictive of overall survival benefit of adjuvant therapy in patients undergoing complete resection but did appear to predict benefit of...
Updated Meta-Analysis Confirms Survival Benefit of Adding Chemotherapy to Radiotherapy in Nasopharyngeal Cancer
In an updated patient-level meta-analysis reported in The Lancet Oncology, Blanchard et al of the Meta-Analysis of Chemotherapy in Nasopharyngeal Carcinoma (MAC-NPC) collaborative group found that the addition of chemotherapy to radiotherapy improved overall survival in patients with nasopharyngeal ...
German Trial Shows Reduced Risk of Venous Thromboembolism With Prophylactic Enoxaparin in Ambulatory Patients With Advanced Pancreatic Cancer
In the German CONKO-004 trial reported in the Journal of Clinical Oncology, Pelzer et al found that prophylactic treatment with the low-molecular-weight heparin enoxaparin reduced the risk of symptomatic venous thromboembolic events in ambulatory patients receiving first-line chemotherapy for...
Improved Pathologic Complete Response Rate With Addition of Bevacizumab to Neoadjuvant Therapy in HER2-Negative Early Breast Cancer
In the phase III ARTemis trial reported in The Lancet Oncology, Earl et al found that the addition of bevacizumab (Avastin) to standard neoadjuvant therapy resulted in a higher pathologic complete response rate in women with HER2-negative early breast cancer. Study Details In this open-label...
Physical Activity Programs Produce Benefits in Patients Receiving Adjuvant Therapy for Breast Cancer
In the Dutch PACES trial reported in the Journal of Clinical Oncology, van Waart et al found that both a moderate/high-intensity supervised exercise program and a low-intensity home-based program provided benefits vs usual care in women undergoing adjuvant chemotherapy for breast cancer. Benefits,...
Poorer Melanoma-Specific Survival With Stage ≥ T2b Tumors With NRAS or BRAF Mutation
In a population-based study reported in JAMA Oncology, Thomas and colleagues found significantly poorer disease-specific survival among melanoma patients with stage ≥ T2b tumors with NRAS or BRAF mutation. Study Details The study included data from 912 U.S. or Australian patients in the...
Germline BRCA Mutations Found in Almost 5% of Patients With Pancreatic Adenocarcinoma
In a study reported in the Journal of Clinical Oncology, Holter et al found that 4.6% of a large clinic population of patients with pancreatic adenocarcinoma harbored pathogenic germline BRCA mutations. The study involved analysis of 306 unselected, consecutive, incident patients with pancreatic...
ASCO Provisional Clinical Opinion Update: HBV Screening for Cancer Patients Before Cancer Therapy
As reported in the Journal of Clinical Oncology by Hwang et al, ASCO has released a provisional clinical opinion update on screening of cancer patients for hepatitis B virus (HBV) infection before cancer treatment to reduce the risk of HBV reactivation. The ASCO consensus panel providing the update ...
Dutch Analysis Questions Breast Cancer Protective Effect of Salpingo-Oophorectomy in Healthy BRCA1/2 Mutation Carriers
In a Dutch study reported in the Journal of the National Cancer Institute, Heemskerk-Gerritsen et al in the Hereditary Breast and Ovarian Cancer in the Netherlands (HEBON) study group found no apparent reduction in the risk for breast cancer with salpingo-oophorectomy in healthy BRCA1/2 mutation...
Meta-Analysis Shows Increased Benefit of EGFR Tyrosine Kinase Inhibitors vs Chemotherapy in Subgroups of Patients With EGFR-Mutant NSCLC
In a meta-analysis reported in the Journal of Clinical Oncology, Lee et al found that increased progression-free survival benefit of EGFR tyrosine kinase inhibitor treatment vs chemotherapy was exhibited in patients with exon 19 deletion, never-smokers, and women. Study Details The meta-analysis...
High Symptom Distress in Children With Advanced Cancer
As reported in the Journal of Clinical Oncology by Wolfe et al, the Pediatric Quality of Life and Evaluation of Symptoms Technology (PediQUEST) study found a high prevalence of disease symptoms in children with advanced cancer, with most symptoms being associated with high distress level. Study...
No Significant Difference in Outcome for ABVD Plus Radiotherapy vs Stanford V in Stage I or II Bulky Mediastinal Hodgkin Lymphoma
As reported in the Journal of Clinical Oncology by Advani et al, a subset analysis of the phase III North American Intergroup E2496 trial showed no significant difference in failure-free or overall survival between ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) plus radiotherapy vs the...
Increased Risk of Long-Term Pulmonary Dysfunction in Survivors of Childhood Cancer Who Received Pulmonary Toxic Treatments
In a single-center study reported in the Journal of Clinical Oncology, Armenian et al found that childhood cancer survivors who had received potentially pulmonary toxic treatment were at a significantly increased risk of long-term pulmonary dysfunction compared with healthy controls. Study Details ...
Targeted Massively Parallel Sequencing Study Indicates Similarity of Somatic Driver Mutations in NSCLC for African American vs European Ancestry
In a study reported in the Journal of Clinical Oncology, Araujo et al used targeted massively parallel sequencing to produce an in-depth molecular profile of non–small cell lung cancer (NSCLC) in African Americans. Comparison with findings in patients of European/white ancestry with NSCLC...
Good Prognosis for Parenthood for Women Treated for Hodgkin Lymphoma During Childhood or Adolescence
In a German study reported in The Lancet Oncology, Brämswig et al found that women treated for Hodgkin lymphoma during childhood or adolescence had a good prognosis for achieving parenthood. Study Details This prospective longitudinal study included 467 female patients aged < 18 years at...
Nilotinib Inferior to Imatinib in First-Line Treatment of Unresectable or Metastatic GIST
In the phase III ENESTg1 trial reported in The Lancet Oncology, Blay et al found that nilotinib (Tasigna) was associated with poorer progression-free survival vs imatinib (Gleevec) as first-line treatment in patients with unresectable or metastatic gastrointestinal stromal tumors (GIST). Trial...
CEP17 or TOP2A Aberrations Predict Benefit of Adjuvant Anthracycline-Based Chemotherapy in Breast Cancer
In a study reported in the Journal of Clinical Oncology, Bartlett et al found that the presence of duplication of chromosome 17 pericentromeric alpha satellite, measured by a centromere enumeration probe (CEP17), and TOP2A aberrations predicted benefit of anthracycline-based adjuvant therapy in...
Donepezil Provides Modest Improvement in Cognitive Function Domains in Irradiated Brain Tumor Survivors
In a phase III trial reported in the Journal of Clinical Oncology, Rapp et al found that the neurotransmitter modulator donepezil may modestly improve some cognitive function domains in patients undergoing cranial irradiation for brain tumors. Improvements were greater in patients with greater...
Maintenance Capecitabine-Bevacizumab Prolongs Time to Second Progression in Metastatic Colorectal Cancer in Dutch Trial
In the phase III CAIRO3 trial reported in The Lancet, Simkens et al of the Dutch Colorectal Cancer Group found that maintenance capecitabine-bevacizumab (Avastin) prolonged the time to second progression vs observation in patients with metastatic colorectal cancer. In this open-label trial, 558...
Hospital and Surgeon Factors Associated With Axillary Lymph Node Evaluation in DCIS
In a study reported in JAMA Oncology, Coromilas et al found that axillary lymph node evaluation is frequently performed in women with ductal carcinoma in situ (DCIS), and a number of hospital or surgeon characteristics are associated with likelihood of evaluation. As noted by the authors, benefit...
Immune Checkpoint Inhibitor Nivolumab Active in Heavily Pretreated Advanced NSCLC
In a phase I cohort expansion trial reported in the Journal of Clinical Oncology, Gettinger et al found that monotherapy with the anti–programmed cell death protein 1 (PD-1) checkpoint inhibitor antibody nivolumab (Opdivo) produced durable responses and promising survival rates in patients...
UK Trial of PET-Directed Therapy Suggests That No Radiotherapy May Be an Option in PET-Negative Early-Stage Hodgkin Lymphoma
In a UK phase III RAPID trial reported in The New England Journal of Medicine, Radford et al compared no further treatment vs involved-field radiotherapy in patients with early-stage Hodgkin lymphoma who had negative positron emission tomography (PET) findings after 3 cycles of doxorubicin,...
Oophorectomy Is Associated With Significantly Reduced Breast Cancer Mortality in Patients With BRCA1 Mutation or Estrogen Receptor–Negative Disease
In a retrospective analysis reported in JAMA Oncology, Metcalfe et al found that oophorectomy in patients with early-stage breast cancer was associated with significantly improved breast cancer survival in women harboring a BRCA1 mutation and in those with estrogen receptor–negative...
Differing Patterns of Breast Cancer Risk After Hormone Therapy With Estrogen Plus Progestin or Estrogen Alone
In an analysis of Women’s Health Initiative (WHI) trials reported in JAMA Oncology, Chlebowski et al found differing patterns of breast cancer risk among women receiving menopausal hormone therapy with estrogen plus progestin or estrogen alone. Women receiving estrogen plus progestin had...
Anti–PD-1 Antibody Pembrolizumab Improves Progression-Free and Overall Survival vs Ipilimumab in Advanced Melanoma
In the phase III KEYNOTE-006 trial reported in The New England Journal of Medicine, Robert et al found that the anti–PD-1 antibody pembrolizumab (Keytruda) increased progression-free and overall survival compared with ipilimumab in patients with advanced melanoma. Study Details In this...
Enzalutamide Improves Patient-Reported Outcomes and Time to Skeletal-Related Event vs Placebo in PREVAIL Trial
The PREVAIL trial showed that enzalutamide (Xtandi) improved overall survival and progression-free survival vs placebo in asymptomatic/minimally symptomatic chemotherapy-naive patients with metastatic castration-resistant prostate cancer. In analyses reported in The Lancet Oncology, Loriot et al...
EGFR Inhibitor Rociletinib Active in EGFR T790M Mutation–Positive NSCLC Previously Treated With EGFR Inhibitors
In a phase I/II study reported in The New England Journal of Medicine, Sequist et al found that rociletinib—an EGFR inhibitor active in the presence and absence of the EGFR T790M mutation known to mediate resistance to available EGFR inhibitors—produced a high response rate in patients...
Safety of Autologous Stem Cell Transplantation Without Hematopoietic Support in Jehovah’s Witnesses With Hematologic Malignancies
In a single-center study reported in the Journal of Clinical Oncology, Ford et al found that autologous stem cell transplantation can be safely performed without hematopoietic support in Jehovah’s Witnesses with hematologic malignancies. Jehovah’s Witnesses traditionally refuse...
Addition of Nivolumab to Ipilimumab Improves Response Rate and Progression-Free Survival in Previously Untreated Advanced Melanoma
In a phase II study reported in The New England Journal of Medicine, Postow et al found that dual checkpoint inhibitor therapy with the anti–CTLA-4 antibody ipilimumab (Yervoy) and the anti–PD-1 monoclonal antibody nivolumab (Opdivo) produced greater response rates and prolonged...
Conditional Survival Estimates After Resection for Intrahepatic Cholangiocarcinoma
In a study reported in JAMA Surgery, Spolverato et al derived 3-year conditional survival estimates for patients in a multi-institutional database who underwent liver resection for intrahepatic cholangiocarcinoma. Among all patients, actuarial overall survival was 16% at 8 years, whereas 3-year...
